Darusentan
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2S)-2-(4,6-Dimethoxypyrimidin-2-yl)oxy-3-methoxy-3,3-di(phenyl)propanoic acid | |
| Clinical data | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Biological half-life | 12.5 hours |
| Identifiers | |
| CAS Number |
171714-84-4  |
| ATC code | None |
| PubChem | CID 177236 |
| IUPHAR/BPS | 3508 |
| ChemSpider |
154336  |
| UNII |
33JD57L6RW |
| ChEMBL |
CHEMBL23261 |
| Chemical data | |
| Formula | C22H22N2O6 |
| Molar mass | 410.42 g/mol |
| |
| |
| (what is this?) (verify) | |
Darusentan (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences,[1] under license from Abbott Laboratories, is developing darusentan for the potential treatment of uncontrolled hypertension.
In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field.[2]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Sunday, September 06, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.